Over the last decade, as other companies—such as AstraZeneca with IL-5 inhibitor Fasenra—struggled to advance candidates for COPD, Regeneron and Sanofi took a more “phenotype-driven approach ...

This approval was based on results from the phase 3 BOREAS (NCT03930732) and NOTUS (NCT04456673) trials, which demonstrated that dupilumab can significantly reduce COPD exacerbations. 2 The first ...

The drug was cleared for use in adults whose COPD symptoms aren’t under control and whose disease is driven by eosinophils, a type of immune cell that can contribute to inflammation. There are ...

If your healthcare provider suspects you have chronic obstructive pulmonary disease (COPD), you will likely be asked to have a chest X-ray. A chest X-ray is a simple, non-invasive imaging technique ...

Chronic obstructive pulmonary disease (COPD), an irreversible form of lung disease, is treated with prescription drugs, lifestyle changes, rehabilitation therapies, and surgery in certain cases. The ...

Dupixent is now cleared for use as an add-on maintenance treatment for adults with a certain kind of chronic obstructive pulmonary disease, or COPD, that can’t be controlled with other medications.

Chronic obstructive pulmonary disease (COPD) is a disease of the respiratory tract that is characterized narrowing of the small airways and destruction of lung tissue. This leads to poor airflow ...

Correspondence to British Thoracic Society, 17, Doughty Street, London WC1N 2PL, UK; bts{at}brit-thoracic.org.uk and Dr Charlotte E Bolton, Nottingham Respiratory Research Unit, University of ...